Abstract
Herbalife will release quarterly results on May 06, 2026, Post Market; investors look for confirmation of its raised preliminary sales outlook, improved EBITDA trajectory, and the impact of recent strategic initiatives on profitability and cash generation.
Market Forecast
Consensus expectations for the quarter point to revenue of 1.29 billion US dollars, adjusted EPS around 0.57, and EBIT near 127.60 million US dollars, implying year-over-year growth of 5.37% for revenue, 56.31% for EPS, and 14.15% for EBIT. Management’s preliminary update indicated net sales growth of 7.50%–8.00% year-over-year and adjusted EBITDA at or above the high end of the prior 155.00–175.00 million US dollars range, reinforcing an improving operational trajectory; no gross margin or net margin guidance was provided.
The core product portfolio remains anchored by Weight Management, which is expected to carry momentum into the quarter as promotions, mix, and personalization initiatives reinforce sell-through. The most promising growth vector is personalized nutrition and digital wellness, aided by the Bioniq asset purchase agreement and Pro2col platform investments, which should broaden the addressable base and raise customer lifetime value over time.
Last Quarter Review
In the previous quarter, Herbalife delivered revenue of 1.28 billion US dollars (up 6.26% year-over-year), a gross profit margin of 172.96%, GAAP net profit attributable to the parent company of 85.40 million US dollars, a net profit margin of 6.66%, and adjusted EPS of 0.45 (up 25.00% year-over-year).
A key highlight was the outperformance versus consensus: revenue exceeded expectations by 38.79 million US dollars and adjusted EPS surpassed the street by 0.02, with EBIT of 121.60 million US dollars up 4.83% year-over-year. By revenue mix, Weight Management represented the largest share of sales, followed by Targeted Nutrition and Energy, Sports and Fitness; applying the latest mix to last quarter’s sales implies approximately 700.90 million US dollars for Weight Management, 384.40 million US dollars for Targeted Nutrition, 157.10 million US dollars for Energy, Sports and Fitness, 21.70 million US dollars for Outer Nutrition, and 20.15 million US dollars for Literature, Promotional and Other.
Current Quarter Outlook
Main business: Weight Management
Weight Management remains the cornerstone of the revenue base and the clearest lever for near-term operating performance. With last quarter’s revenue mix indicating roughly 700.90 million US dollars, this category’s contribution gives Herbalife the scale to translate modest volume gains and disciplined pricing into meaningful operating leverage. The company’s preliminary update, raising expected first-quarter net sales growth to 7.50%–8.00%, suggests momentum that likely includes continued resilience in Weight Management sell-through as distributors cycle last year’s modest growth baseline.
On profitability, the earnings setup benefits from cost-control and efficiency programs that help offset input and logistics variability. Pricing discipline and product mix within Weight Management will be key to gross margin direction; if volumes hold and promos remain balanced, there is room for incremental contribution margin improvement, even as the reported gross margin will ultimately reflect mix effects across geographies and products. Investor attention will also center on the conversion of Weight Management revenue into cash flow, because incremental cash generation would reinforce the deleveraging narrative underway after the recent refinancing steps.
From a demand perspective, execution at the distributor level remains crucial for repeat purchases and customer engagement. The company’s initiatives around personalization and digital engagement can also create cross-selling into Weight Management customers, potentially lifting average order value and retention. The cadence of reorder activity during the quarter, combined with inventory movement and sell-in/sell-through patterns, will shape how much of the raised net sales outlook ultimately translates into EBIT and EPS upside versus consensus.
Most promising business: Personalized nutrition and digital wellness
Herbalife has moved to accelerate personalization, highlighted by its agreement to acquire certain assets from Bioniq for 55.00 million US dollars, with an additional contingent earn-out of up to 95.00 million US dollars based on performance. Distribution is planned to begin in the United States and select European countries this year, with broader rollouts envisioned thereafter, positioning personalized formulations to complement the existing Targeted Nutrition portfolio (which, based on last quarter’s mix, approximated 384.40 million US dollars of revenue). The introduction of test-driven or data-guided supplement regimens has the potential to increase average spend and reduce churn as offerings become more tailored to customer needs.
The company’s Pro2col wellness platform has also attracted strategic attention, including a 10% stake investment reportedly valued at 7.50 million US dollars by Cristiano Ronaldo. This combination of product personalization and elevated brand visibility can stimulate demand across both Weight Management and Targeted Nutrition, while creating a high-engagement funnel that yields cross-category purchase behavior. Near-term, the investment is a branding and traffic catalyst; medium-term, it can support a richer ecosystem of first-party customer data, fueling a more precise product roadmap and upsell engine.
From a financial perspective, management’s preliminary outlook for Q1 net sales growth and adjusted EBITDA at or above the high end of guidance implies early signs that the personalization roadmap can complement core-category performance rather than dilute it. While the revenue contribution from personalization-specific initiatives may be modest in the current quarter, investors will look for leading indicators: customer acquisition trends, attach rates to existing bundles, and any commentary on early reorder cohorts. These data points will help quantify how much personalized offerings can lift unit economics over time.
Factors most likely to impact the stock this quarter
The first major swing factor is the magnitude of the reported beat or miss relative to both consensus and management’s raised preliminary update. Consensus pencils in revenue of 1.29 billion US dollars and adjusted EPS of about 0.57, implying year-over-year growth of 5.37% and 56.31% respectively; investors will focus on whether realized net sales growth lands near the 7.50%–8.00% range and whether EBITDA outturn aligns with or exceeds the high end of management’s earlier 155.00–175.00 million US dollars guidance. The quality of the print will be judged on breadth (number of regions and product categories contributing) and durability (order patterns and early-quarter indicators for the next period).
A second factor is balance sheet progress and cost of capital. Herbalife priced 800.00 million US dollars of senior secured notes due 2033 at a 7.75% coupon, with closing slated for April 29, 2026, and outlined a broader plan to secure 1.55 billion US dollars of facilities to refinance and extend maturities of senior secured debt. Taken together, these steps should alleviate near-dated refinancing risk and can lower overall interest expense versus the 12.25% notes due 2029 they intend to retire, although the interest expense profile will transition over time and be more visible from Q2 onward. Clear communication on the path to net leverage reduction, free cash flow priorities, and any expected changes in interest cost will be closely scrutinized by the market.
The third factor is execution on strategic growth levers. Investors will watch for tangible progress on the Bioniq asset integration timeline, distributor training and go-to-market readiness for the initial US and European rollouts, and early usage metrics from Pro2col. Commentary on customer engagement, cross-sell synergies, and how personalization is embedded into the selling system will guide expectations for revenue per active customer and retention improvement. Any early read-throughs on marketing efficiency or improvements in reorder behavior can reinforce the thesis that personalization drives higher lifetime value without meaningfully increasing customer acquisition costs.
Analyst Opinions
Bullish vs. Bearish ratio: Bullish 100% vs. Bearish 0% among the recent views captured in the period from January 01, 2026 to April 29, 2026. The majority view is bullish.
Maxim Group reiterated a Buy rating on Herbalife with a 25.00 US dollars price target, highlighting turnaround momentum, the upside from personalized nutrition, and attractive valuation. The analyst underscored that Q1 performance indicators—both in the company’s preliminary net sales growth of 7.50%–8.00% and the expectation for adjusted EBITDA to meet or exceed the high end of guidance—support a multi-quarter improvement trajectory. In this view, the combination of steady core-category execution, increased brand resonance via high-profile partnerships, and a pipeline of personalized products provides visibility into EPS and cash flow inflection.
From an analytical standpoint, the thesis is reinforced by a few measurable pillars. First, consensus forecast calls for revenue of 1.29 billion US dollars, EBIT of 127.60 million US dollars, and adjusted EPS of 0.57, implying year-over-year growth of 5.37%, 14.15%, and 56.31% respectively. If Herbalife prints in line with the raised preliminary outlook, the setup creates positive operating leverage, given the cost base actions in place and the typically high incremental margins in the direct-selling model when volumes expand. Second, deleveraging optionality improves as refinancing reduces weighted average borrowing costs and extends maturities; as this filters through interest expense in subsequent quarters, it can add a tailwind to net income growth and stabilize equity multiples.
Third, the strategic expansion into personalization via Bioniq and digital wellness via Pro2col is a structural driver that broadens the funnel and deepens engagement. Institutional commentary points to the personalization theme as central to the medium-term growth runway, potentially increasing customer lifetime value through higher frequency and tailored bundles. While the near-term revenue impact is likely modest, analysts see this as an important differentiator that can support continued mix enhancement and defend gross profit dollars as the company scales its data-driven selling approaches.
In sum, the bullish camp expects Herbalife to execute a beat-and-raise cadence or, at minimum, confirm the raised preliminary outlook with healthy color on Q2 trends, improved cash generation, and clearer interest expense trajectories post-refinancing. Confirmation of cross-sell traction and early personalization metrics would further validate the medium-term story. Given the current consensus and management’s updates, the balance of probabilities supports a constructive stance heading into the print, with attention focused on the breadth of growth and the visibility of deleveraging in 2026.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments